Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients
Strides For Life I: A Randomized Controlled Trial of Induction of Positive Affect to Increase Physical Activity in Early Stage Lung Cancer Survivors
Status: Enrolling
Updated:  2/6/2018
Weill-Cornell Medical College
mi
from
New York, NY
Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients
Strides For Life I: A Randomized Controlled Trial of Induction of Positive Affect to Increase Physical Activity in Early Stage Lung Cancer Survivors
Status: Enrolling
Updated: 2/6/2018
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
Status: Enrolling
Updated:  2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
Status: Enrolling
Updated: 2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated:  2/6/2018
Premiere Oncology
mi
from
Santa Monica, CA
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated: 2/6/2018
Premiere Oncology
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated:  2/6/2018
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated: 2/6/2018
University of Colorado Health Sciences Ctr.
mi
from
Aurora, CO
Click here to add this to my saved trials
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated:  2/6/2018
The Mayo Clinic
mi
from
Rochester, MN
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated: 2/6/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated:  2/6/2018
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated: 2/6/2018
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated:  2/6/2018
The Beatson West of Scotland Cancer Centre
mi
from
Glasgow,
A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
An Open-Label Study to Characterize the Pharmacokinetic Parameters of Erlotinib (Tarceva®, OSI-774) in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaired Hepatic Function
Status: Enrolling
Updated: 2/6/2018
The Beatson West of Scotland Cancer Centre
mi
from
Glasgow,
Click here to add this to my saved trials
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated:  2/7/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 2/7/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated:  2/7/2018
Massachusetts General Hospital
mi
from
Boston, MA
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 2/7/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated:  2/7/2018
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
A Multi-Institutional, Phase II Open-Label Study of AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Status: Enrolling
Updated: 2/7/2018
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Phase I Evaluation of Intravenous Carboplatin With Weekly Paclitaxel and Bevacizumab in Patients Undergoing Neoadjuvant Chemotherapy for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Enrolling
Updated:  2/7/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Phase I Evaluation of Intravenous Carboplatin With Weekly Paclitaxel and Bevacizumab in Patients Undergoing Neoadjuvant Chemotherapy for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Status: Enrolling
Updated: 2/7/2018
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
Status: Enrolling
Updated:  2/7/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
Status: Enrolling
Updated: 2/7/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/8/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/8/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/8/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/8/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/8/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/8/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/8/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/8/2018
MedStar Georgetown University Hospital
mi
from
Washington,
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/8/2018
Montefiore Medical Center-Weiler Hospital
mi
from
Bronx, NY
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/8/2018
Montefiore Medical Center-Weiler Hospital
mi
from
Bronx, NY
Click here to add this to my saved trials
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  2/8/2018
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
A 2-arm Randomized Phase II Study of Carboplatin, Paclitaxel Plus Reovirus Serotype-3 Dearing Strain (Reolysin) vs. Carboplatin and Paclitaxel in the First Line Treatment of Patients With Recurrent or Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 2/8/2018
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer
Status: Enrolling
Updated:  2/8/2018
University of California at San Francisco
mi
from
San Francisco, CA
Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer
A Phase II Study of Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Locally Advanced or Primary Metastatic Breast Cancer
Status: Enrolling
Updated: 2/8/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated:  2/8/2018
The Hartford Hospital
mi
from
Hartford, CT
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated: 2/8/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated:  2/8/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated: 2/8/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated:  2/8/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated: 2/8/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
NM404 as an Imaging Agent in Patients With NSCLC
NM404 as an Imaging Agent in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated:  2/8/2018
University of Wisconsin Carbone Comprehensive Cancer Center
mi
from
Madison, WI
NM404 as an Imaging Agent in Patients With NSCLC
NM404 as an Imaging Agent in Patients With Non-small Cell Lung Cancer (NSCLC)
Status: Enrolling
Updated: 2/8/2018
University of Wisconsin Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients With Advanced Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated:  2/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients With Advanced Solid Tumors Refractory to Standard Therapy
Status: Enrolling
Updated: 2/8/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors
Status: Enrolling
Updated:  2/8/2018
Southern Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors
Status: Enrolling
Updated: 2/8/2018
Southern Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors
Status: Enrolling
Updated:  2/8/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors
Status: Enrolling
Updated: 2/8/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study
Status: Enrolling
Updated:  2/8/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer
Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study
Status: Enrolling
Updated: 2/8/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated:  2/8/2018
Massachusetts General Hosptial
mi
from
Boston, MA
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated: 2/8/2018
Massachusetts General Hosptial
mi
from
Boston, MA
Click here to add this to my saved trials
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated:  2/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer
Status: Enrolling
Updated: 2/8/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated:  2/8/2018
Indiana University Health Hospital
mi
from
Indianapolis, IN
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated: 2/8/2018
Indiana University Health Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated:  2/8/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated: 2/8/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated:  2/8/2018
Sidney and Lois Eskenazi Hospital
mi
from
Indianapolis, IN
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated: 2/8/2018
Sidney and Lois Eskenazi Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated:  2/8/2018
Spring Mill Medical Center
mi
from
Indianapolis, IN
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
Status: Enrolling
Updated: 2/8/2018
Spring Mill Medical Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Detroit, MI
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Oklahoma City, OK
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Boston, MA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Cleveland, OH
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Miami, FL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Lake Success, NY
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Lake Success, NY
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Chapel Hill, NC
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Charlotte, NC
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Memphis, TN
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
San Antonio, TX
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Birmingham, AL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
San Francisco, CA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Stanford, CA
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated:  2/8/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer
Status: Enrolling
Updated: 2/8/2018
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials